We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) ended the recent trading session at $58.96, demonstrating a +1.85% change from the preceding day's closing price. This change outpaced the S&P 500's 0.26% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.36%.
The stock of biopharmaceutical company has fallen by 2.49% in the past month, lagging the Medical sector's loss of 1.19% and the S&P 500's gain of 5.98%.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 30, 2026. The company is expected to report EPS of $1.45, down 19.44% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $10.96 billion, indicating a 2.19% downward movement from the same quarter last year.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.28 per share and revenue of $47.04 billion. These results would represent year-over-year changes of +2.11% and -2.4%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Bristol Myers Squibb presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 9.22. This represents a discount compared to its industry average Forward P/E of 21.43.
It is also worth noting that BMY currently has a PEG ratio of 0.17. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.6 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today
Bristol Myers Squibb (BMY - Free Report) ended the recent trading session at $58.96, demonstrating a +1.85% change from the preceding day's closing price. This change outpaced the S&P 500's 0.26% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.36%.
The stock of biopharmaceutical company has fallen by 2.49% in the past month, lagging the Medical sector's loss of 1.19% and the S&P 500's gain of 5.98%.
Investors will be eagerly watching for the performance of Bristol Myers Squibb in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on April 30, 2026. The company is expected to report EPS of $1.45, down 19.44% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $10.96 billion, indicating a 2.19% downward movement from the same quarter last year.
BMY's full-year Zacks Consensus Estimates are calling for earnings of $6.28 per share and revenue of $47.04 billion. These results would represent year-over-year changes of +2.11% and -2.4%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Bristol Myers Squibb. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.05% upward. Bristol Myers Squibb presently features a Zacks Rank of #3 (Hold).
In terms of valuation, Bristol Myers Squibb is currently trading at a Forward P/E ratio of 9.22. This represents a discount compared to its industry average Forward P/E of 21.43.
It is also worth noting that BMY currently has a PEG ratio of 0.17. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.6 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.